로딩 중…
StockDiggingStockDigging

REYON PHARMACEUTICAL CO., LTD

102460· KOSPI
₩9,890+0.10%
2026-06-19

Price Chart

REYON PHARMACEUTICAL CO., LTD-12.56%

Financials

Investment Metrics(as of 2026-06-19)

MetricValue
Size
Market Cap183.82B KRW
Revenue145.22B KRW
Net Income-23.79B KRW
Total Assets454.38B KRW
Net Assets209.58B KRW
Employees449
Value
P/B0.88x
P/S1.27x
FCF Yield-8.13%
Profitability
ROE-11.35%
ROA-5.24%
Op. Margin-22.81%
Revenue Growth-1.92%
Earnings Growth-5068.68%
Financial Health
Debt Ratio216.80%
Total Debt217.88B KRW
FCF-14.95B KRW
Cash4.29B KRW
Current Ratio0.52x
Dividend
Div. Yield1.50%
Div. Growth0.00%
Performance
1Y Return-12.56%
1M Return-13.78%
From 52W High-31.46%
1Y MDD-28.87%
Trading
Volume81,824 shares
Foreign Own.1.17%
Per Share
EPS-2,184 KRW
BPS11,427 KRW

Company Info

CEO 정순옥, 유용환 (각자 대표이사)
Employees 449
Founded 1964
HQ 서울특별시 강남구, KR

Headquartered in Gangnam-gu, Seoul, E-Yang Pharmaceutical was established in 1964, promoting the domestic production of pharmaceutical raw materials and expanding into new technology business finance in 2017. The company holds various prescription medicines for multiple indications, exclusively supplies original medicines like Optiray, and sells active pharmaceutical ingredients such as Tacrolimus. To become a global bio & chemical pharmaceutical company, it collaborates with bio-ventures on new drug development, with its KGMP-certified Chungju factory driving an R&D business model.